Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Pfizer-BioNTech Ink COVID-19 Vaccine Manufacturing Pact For Latin America

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have partnered with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture its COVID-19 vaccine for…
byVandana Singh
August 26, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have partnered with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture its COVID-19 vaccine for distribution within Latin America.
  • Technical transfer, on-site development, and equipment installation activities will begin immediately. Per the agreement, Eurofarma will obtain the drug product from facilities in the U.S., and manufacturing of finished doses will commence in 2022. 
  • At total operational capacity, the annual production is expected to exceed 100 million finished doses. 
  • All doses will exclusively be distributed within Latin America.
  • Related: Pfizer, BioNTech Now Seeking Full Approval For Third COVID-19 Vaccine Dose
  • Price Action: PFE shares are down 0.08% at $47.47, while BNTX stock is down 1.60% at $370 during the premarket session on the last check Thursday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AbbVie Announced Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

By Charles Gross
Today, 11:05 PM
AbbVie (NYSE: ABBV), today announced that RINVOQ is now listed as a special authorization medication or exception medication status on the formularies of Alberta1, New Brunswick2, Ontario3, Quebec4 and Saskatchewan5 for the treatment of adults with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

ABBV